항체약물접합체(ADC) 위탁생산 시장 보고서(2026년)

Antibody-drug conjugates (ADC) contract manufacturing involves outsourced production services offered by specialized contract development and manufacturing organizations (CDMOs) to produce antibody-drug conjugates. ADCs are intricate biopharmaceuticals that link an antibody with a cytotoxic drug, engineered to target and eliminate specific cancer cells while reducing harm to healthy cells.

The main types of antibody-drug conjugates contract manufacturing are immunoglobulin G1 (IgG1) and immunoglobulin G4 (IgG4). Immunoglobulin G1 (IgG1) is one of the four subclasses of Immunoglobulin G (IgG), a type of antibody present in the blood and extracellular fluid. The various linkers include cleavable linkers and non-cleavable linkers, used for multiple conditions such as myeloma, lymphoma, and breast cancer, among others, and are applied across several phases such as clinical and commercial.

Tariffs have influenced the antibody drug conjugates contract manufacturing market by increasing costs of imported biologic raw materials, linkers, and cytotoxic payload components. Clinical and commercial manufacturing phases are most affected, particularly in regions reliant on international supply chains. Higher tariffs may increase development costs. However, tariffs are encouraging regional manufacturing expansion and localized supply chains.

The antibody drug conjugates contract manufacturing market research report is one of a series of new reports from The Business Research Company that provides antibody drug conjugates contract manufacturing market statistics, including antibody drug conjugates contract manufacturing industry global market size, regional shares, competitors with a antibody drug conjugates contract manufacturing market share, detailed antibody drug conjugates contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the antibody drug conjugates contract manufacturing industry. This antibody drug conjugates contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antibody drug conjugates contract manufacturing market size has grown strongly in recent years. It will grow from $10.45 billion in 2025 to $11.45 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to growth in targeted cancer therapies, complexity of adc production, limited in-house manufacturing capabilities, early clinical success of adcs, regulatory compliance requirements.

The antibody drug conjugates contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $16.5 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to expanding oncology pipelines, increasing approvals of adc therapies, rising demand for commercial-scale production, investment in specialized manufacturing facilities, long-term cdmo partnerships. Major trends in the forecast period include rising outsourcing of complex biologic manufacturing, growing demand for oncology-focused cdmo services, increased focus on high-potency payload handling, expansion of clinical-stage adc manufacturing, higher adoption of advanced conjugation technologies.

The expanding biopharmaceutical industry is anticipated to drive the growth of the antibody-drug conjugates contract manufacturing market in the coming years. The biopharmaceutical sector focuses on developing, producing, and commercializing drugs derived from biological sources, employing biotechnology and molecular biology to create innovative therapies and treatments. This industry is growing due to rapid advancements in biotechnology, increasing demand for personalized medicine, and rising investments in research and development for novel therapies and treatments. Antibody-drug conjugates (ADCs) contract manufacturing supports the biopharmaceutical sector by providing specialized production services that facilitate the development and commercialization of these advanced therapies. Biopharmaceutical companies can efficiently scale up production and maintain high-quality standards while concentrating on their core research and development activities. For example, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, total pharmaceutical production in Europe reached €390,000 million ($422,803 million) in 2023, up from €363,300 million ($393,857 million) in 2022. Thus, the growing biopharmaceutical industry is driving the expansion of the antibody-drug conjugates contract manufacturing market.

Major companies operating in the antibody-drug conjugates contract manufacturing market are concentrating on developing innovative solutions, such as single-use reactors, to boost production flexibility, minimize contamination risks, and simplify the manufacturing process, ultimately enhancing the efficiency and scalability of ADC production. Single-use reactors are transforming the field of antibody-drug conjugates (ADCs) contract manufacturing by offering a flexible, efficient, and contamination-free approach for producing these complex biologics. For example, in September 2024, MilliporeSigma, a US-based life sciences company, introduced the Mobius ADC Reactor, a single-use reactor. The Mobius ADC Reactor is specifically engineered to manufacture antibody-drug conjugates (ADCs) efficiently. It incorporates advanced mixing and control technologies that streamline conjugation, improve scalability, and ensure greater consistency. This innovative reactor enables higher yields and better quality control in ADC production, meeting the increasing demand for targeted cancer therapies with enhanced safety and efficacy.

In March 2024, Johnson & Johnson, a US-based pharmaceutical, biotechnology, and medical technologies corporation, acquired Ambrx Biopharma Inc. for $2.0 billion. Through this acquisition, Johnson & Johnson intends to strengthen its pipeline of advanced therapies by incorporating Ambrx's innovative drug development technologies and broadening its biologics and targeted treatment capabilities. Ambrx Biopharma Inc. is a US-based biotechnology firm that specializes in developing state-of-the-art therapies, including antibody-drug conjugates (ADCs).

Major companies operating in the antibody drug conjugates contract manufacturing market are Lonza Group AG, Catalent Inc., Recipharm AB, Curia, KBI Biopharma, Alcami Corporation, BioVectra Inc., Axplora, Abzena PLC, Cerbios-Pharma SA, Aurigene Pharmaceutical Services Ltd., Sterling Pharma Solutions, Formosa Laboratories, Avid Bioservices Inc., EirGenix Inc., Creative Biolabs, Sartorius AG, Sigma-Aldrich, ImmunoGen Inc., Eli Lilly and Company

North America was the largest region in the antibody drug conjugates contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody drug conjugates contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibody drug conjugates contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibody drug conjugates contract manufacturing market includes revenues earned by entities by providing process development, scale-up and manufacturing, analytical testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibody Drug Conjugates Contract Manufacturing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses antibody drug conjugates contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibody drug conjugates contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antibody drug conjugates contract manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Immunoglobulin G1(Igg1); Immunoglobulin G4(Igg4)
• 2) By Linker: Cleavable Linker; Non-Cleavable Linker
• 3) By Condition: Myeloma; Lymphoma; Breast Cancer; Other Conditions
• 4) By Phase: Clinical; Commercial
• Subsegments:
• 1) By Immunoglobulin G1 (IgG1): High-Effector Function ADCs; Fc-Mediated Cytotoxicity-Enabled ADCs; Stable Conjugation IgG1 ADCs; Oncology-Targeted IgG1 ADCs
• 2) By Immunoglobulin G4 (IgG4): Reduced Effector Function ADCs; Low Immunogenicity IgG4 ADCs; Site-Specific Conjugation IgG4 ADCs; Precision-Targeted IgG4 ADCs
• Companies Mentioned: Lonza Group AG; Catalent Inc.; Recipharm AB; Curia; KBI Biopharma; Alcami Corporation; BioVectra Inc.; Axplora; Abzena PLC; Cerbios-Pharma SA; Aurigene Pharmaceutical Services Ltd.; Sterling Pharma Solutions; Formosa Laboratories; Avid Bioservices Inc.; EirGenix Inc.; Creative Biolabs; Sartorius AG; Sigma-Aldrich; ImmunoGen Inc.; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Antibody Drug Conjugates Contract Manufacturing Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Antibody Drug Conjugates Contract Manufacturing Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Antibody Drug Conjugates Contract Manufacturing Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Antibody Drug Conjugates Contract Manufacturing Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Outsourcing Of Complex Biologic Manufacturing
  • 4.2.2 Growing Demand For Oncology-Focused Cdmo Services
  • 4.2.3 Increased Focus On High-Potency Payload Handling
  • 4.2.4 Expansion Of Clinical-Stage Adc Manufacturing
  • 4.2.5 Higher Adoption Of Advanced Conjugation Technologies

5. Antibody Drug Conjugates Contract Manufacturing Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biopharmaceutical Companies
• 5.3 Oncology Drug Developers
• 5.4 Clinical Research Organizations
• 5.5 Biotechnology Firms

6. Antibody Drug Conjugates Contract Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Antibody Drug Conjugates Contract Manufacturing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Antibody Drug Conjugates Contract Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Antibody Drug Conjugates Contract Manufacturing Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Antibody Drug Conjugates Contract Manufacturing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Antibody Drug Conjugates Contract Manufacturing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Antibody Drug Conjugates Contract Manufacturing Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Antibody Drug Conjugates Contract Manufacturing Market Segmentation

• 9.1. Global Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immunoglobulin G1(Igg1), Immunoglobulin G4(Igg4)
• 9.2. Global Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Linker, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cleavable Linker, Non-Cleavable Linker
• 9.3. Global Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Myeloma, Lymphoma, Breast Cancer, Other Conditions
• 9.4. Global Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Clinical, Commercial
• 9.5. Global Antibody Drug Conjugates Contract Manufacturing Market, Sub-Segmentation Of Immunoglobulin G1 (IgG1), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• High-Effector Function ADCs, Fc-Mediated Cytotoxicity-Enabled ADCs, Stable Conjugation IgG1 ADCs, Oncology-Targeted IgG1 ADCs
• 9.6. Global Antibody Drug Conjugates Contract Manufacturing Market, Sub-Segmentation Of Immunoglobulin G4 (IgG4), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Reduced Effector Function ADCs, Low Immunogenicity IgG4 ADCs, Site-Specific Conjugation IgG4 ADCs, Precision-Targeted IgG4 ADCs

10. Antibody Drug Conjugates Contract Manufacturing Market Regional And Country Analysis

• 10.1. Global Antibody Drug Conjugates Contract Manufacturing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Antibody Drug Conjugates Contract Manufacturing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market

• 11.1. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Antibody Drug Conjugates Contract Manufacturing Market

• 12.1. China Antibody Drug Conjugates Contract Manufacturing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Antibody Drug Conjugates Contract Manufacturing Market

• 13.1. India Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Antibody Drug Conjugates Contract Manufacturing Market

• 14.1. Japan Antibody Drug Conjugates Contract Manufacturing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Antibody Drug Conjugates Contract Manufacturing Market

• 15.1. Australia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Antibody Drug Conjugates Contract Manufacturing Market

• 16.1. Indonesia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Antibody Drug Conjugates Contract Manufacturing Market

• 17.1. South Korea Antibody Drug Conjugates Contract Manufacturing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Antibody Drug Conjugates Contract Manufacturing Market

• 18.1. Taiwan Antibody Drug Conjugates Contract Manufacturing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Antibody Drug Conjugates Contract Manufacturing Market

• 19.1. South East Asia Antibody Drug Conjugates Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Antibody Drug Conjugates Contract Manufacturing Market

• 20.1. Western Europe Antibody Drug Conjugates Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Antibody Drug Conjugates Contract Manufacturing Market

• 21.1. UK Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Antibody Drug Conjugates Contract Manufacturing Market

• 22.1. Germany Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Antibody Drug Conjugates Contract Manufacturing Market

• 23.1. France Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Antibody Drug Conjugates Contract Manufacturing Market

• 24.1. Italy Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Antibody Drug Conjugates Contract Manufacturing Market

• 25.1. Spain Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Antibody Drug Conjugates Contract Manufacturing Market

• 26.1. Eastern Europe Antibody Drug Conjugates Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Antibody Drug Conjugates Contract Manufacturing Market

• 27.1. Russia Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Antibody Drug Conjugates Contract Manufacturing Market

• 28.1. North America Antibody Drug Conjugates Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Antibody Drug Conjugates Contract Manufacturing Market

• 29.1. USA Antibody Drug Conjugates Contract Manufacturing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Antibody Drug Conjugates Contract Manufacturing Market

• 30.1. Canada Antibody Drug Conjugates Contract Manufacturing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Antibody Drug Conjugates Contract Manufacturing Market

• 31.1. South America Antibody Drug Conjugates Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Antibody Drug Conjugates Contract Manufacturing Market

• 32.1. Brazil Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Antibody Drug Conjugates Contract Manufacturing Market

• 33.1. Middle East Antibody Drug Conjugates Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Antibody Drug Conjugates Contract Manufacturing Market

• 34.1. Africa Antibody Drug Conjugates Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Antibody Drug Conjugates Contract Manufacturing Market, Segmentation By Type, Segmentation By Linker, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Antibody Drug Conjugates Contract Manufacturing Market Regulatory and Investment Landscape

36. Antibody Drug Conjugates Contract Manufacturing Market Competitive Landscape And Company Profiles

• 36.1. Antibody Drug Conjugates Contract Manufacturing Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Antibody Drug Conjugates Contract Manufacturing Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Antibody Drug Conjugates Contract Manufacturing Market Company Profiles
  • 36.3.1. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Catalent Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Recipharm AB Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Curia Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. KBI Biopharma Overview, Products and Services, Strategy and Financial Analysis

37. Antibody Drug Conjugates Contract Manufacturing Market Other Major And Innovative Companies

• Alcami Corporation, BioVectra Inc., Axplora, Abzena PLC, Cerbios-Pharma SA, Aurigene Pharmaceutical Services Ltd., Sterling Pharma Solutions, Formosa Laboratories, Avid Bioservices Inc., EirGenix Inc., Creative Biolabs, Sartorius AG, Sigma-Aldrich, ImmunoGen Inc., Eli Lilly and Company

38. Global Antibody Drug Conjugates Contract Manufacturing Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Antibody Drug Conjugates Contract Manufacturing Market

40. Antibody Drug Conjugates Contract Manufacturing Market High Potential Countries, Segments and Strategies

• 40.1 Antibody Drug Conjugates Contract Manufacturing Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Antibody Drug Conjugates Contract Manufacturing Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Antibody Drug Conjugates Contract Manufacturing Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer